Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is based in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. operates as a subsidiary of Alumis Inc.
Metrics to compare | SLRN | Peers Peers - average of corresponding metrics from companies closely matching SLRN: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLRNPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 49.2% | |
Fair Value Upside | Unlock | 0.0% | 7.4% | Unlock |